The White House has withdrawn Heidi Overton's nomination to lead the US Food and Drug Administration (FDA), ending her bid before a Senate committee vote amid doubts about Republican support.

The physician and senior Trump administration aide faced scrutiny over her role in efforts to alter childhood vaccine recommendations, her views on abortion medication and questions about her independence from the president. The decision was announced on 17 November, ahead of a scheduled committee vote the following day.

Vaccine Policy Became a Major Hurdle

Overton's support for a Trump executive order calling for fewer federally recommended childhood vaccinations and splitting the combined measles, mumps and rubella (MMR) vaccine into separate shots drew concern from medical groups and lawmakers. The order was promoted in August, with Overton appearing alongside Trump.

Senator Bill Cassidy, the Republican chairman of the Senate health committee and a physician, had described her role in the vaccine-policy effort as 'almost disqualifying'.

At her September confirmation hearing, Overton rejected Trump's claim that the MMR vaccine was lethal, saying it was safe and effective and that vaccines currently on the US market met FDA safety standards.

Her position left senators weighing both her stated support for approved vaccines and her involvement in administration policy that challenged the existing childhood vaccination schedule.

Abortion Pill Views Further Undermined Overton's FDA Bid

Overton's record on mifepristone, the medication used in abortion care, also became a source of scrutiny. She had criticised the Biden administration's loosening of restrictions on dispensing the drug and previously argued for tighter regulation.

During her hearing, however, she acknowledged that the medicine had met FDA safety and efficacy standards and said she would follow those statutory standards as commissioner.

Some Republicans pressed for stronger commitments on abortion policy, while senators Susan Collins and Lisa Murkowski, who support abortion access, had not publicly committed to advancing her nomination. Democrats were expected to oppose her, meaning Overton needed the support of all 12 Republicans on the 21-member committee to advance her nomination.

Her nomination also attracted criticism over the FDA's authorisation of fruit-flavoured vaping products, which Overton defended at the hearing as potentially helping some adults quit smoking.

Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement criticised Overton, alleging that she had obstructed parts of their policy agenda and questioning her corporate ties

Cassidy Disputes White House Explanation

The White House said Overton lacked sufficient support on Capitol Hill to proceed. Cassidy disputed that assessment, saying he believed she could have passed both the committee and the full Senate.

Cassidy said anti-abortion Republicans had sought assurances from the administration on abortion-related policies, but the White House withdrew Overton's nomination rather than provide those commitments.

The withdrawal leaves the FDA without a Senate-confirmed commissioner. Kyle Diamantas, the agency's former top food official and current deputy commissioner for food, is serving as acting commissioner.

The administration is reportedly considering other candidates, including Senator Roger Marshall, a former obstetrician who recently lost his re-election bid, but no replacement has been announced.

The FDA is also conducting a safety review of mifepristone, with findings expected by March 2027. Whoever takes the permanent role will inherit a politically contentious agency overseeing medicines, vaccines, tobacco products and food safety, with disputes over scientific independence and reproductive policy still unresolved.